ONCBeiGeneFinished
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma · Head and Neck Cancer
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.7
2 insiders sold shares within a month
Since Aug 3, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 160 (final count)
- Started
- Aug 2, 2023
- Main results expected
- Jun 17, 2025
- Fully finished
- Jul 23, 2026
- Results posted
- Jul 14, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate (ORR)
Measured over: Up to 21.2 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.7, since 2026-08-03, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05909904 · record last updated 2026-09-01 · checked 2026-11-09 15:47 UTC